Effect of Consumption of a Milk Product Designed for Lactating Women on Human Milk Composition

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorInstituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri

About this trial

Vulnerable populations, who have deficient diets, may produce human milk (HML) that is not adequate in all nutrients and this will have consequences on the growth and development of the child. In 2021 at IDIP, a specific milk product for pregnant and lactating women Super Mil Mamá ( SMM, whole milk powder fortified with multiple vitamins, minerals and DHA ) has been designed and developed as part of a key strategy to incorporate in public policies for the first 1000 days of life. However, the potential benefits of this product have not yet been evaluated at the population level.

The main objective is to evaluate the effect of the consumption of a milk product (SMM) designed for lactating women on the composition of human milk and the nutritional status of iron and DHA in infant red blood cells in a vulnerable population through a randomized, triple-blind, controlled clinical trial.

Specific objectives To compare the concentrations of DHA, Vitamins A, E, and D, Iron, Iodine, Zinc and Calcium in human milk before and after dietary supplementation with SMM.

To compare the concentrations of DHA, Vitamins A, E, D and Zinc in blood and the nutritional status of maternal iron before and after dietary supplementation with SMM.

To analyze the relationship between micronutrients measured in maternal blood and human milk after dietary supplementation with SMM.

To compare the concentrations of micronutrients measured in blood and human milk in women who received SMM and those who received commercial milk (CM) at the end of supplementation.

To compare the iron nutritional status and DHA content in red blood cells of infants of mothers who consumed SMM or LC.

To evaluate the relationship between the concentration of micronutrients in human milk and infant growth during the first six months of life.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Women who attend their child's first check-up within the first month of life, who breastfeed their children, and who consume milk regularly.

Disqualifiers

Women who have had multiple pregnancies, who receive vitamin or mineral supplements that interfere with the results of the study, and/or women with malabsorption diseases.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Fortified powder milk

    Dietary supplement

    Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.

  • Powder milk

    Other intervention

    Commercial powder milk constitutes dehydrated commercially available cow's milk, which is fortified with Vitamins A and D by law.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Super 1.000 MamáExperimental treatment 1 intervention
Group B: Leche comercialSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

breast milk DHA concentration

concentration of DHA in breast milk expressed as a percentage of DHA with respect to the total fatty acids contained in the analyzed sample

Time frame
breast milk DHA concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)
2

breast milk Vitamin A concentration

Retinol concentration in breast milk expressed in μmol/L and μg/g fat contained in the analyzed sample

Time frame
breast milk Vitamin A concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)
3

breast milk Vitamin E concentration

α-tocopherol concentration in breast milk expressed in μmol/L and μg/g fat contained in the analyzed sample

Time frame
breast milk Vitamin E concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)
4

breast milk Vitamin D concentration

25-hidroxi vitamin D concentration in breast milk expressed in ng/ml

Time frame
breast milk Vitamin D concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)

Secondary outcomes

1

mother red blood cell DHA concentration

concentration of DHA in mother red blood cell expressed as a percentage of DHA with respect to the total fatty acids contained in the analyzed sample

Time frame
mother serum DHA concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)
2

mother Vit A concentration

Retinol concentration in mother serum expressed in μmol/L

Time frame
mother Vit A concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)
3

mother Vit E concentration

α-tocopherol concentration in mother serum expressed in μmol/L

Time frame
mother Vit E concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)
4

mother Vit D concentration

25-hidroxi vitamin D concentration in mother serum expressed in ng/ml

Time frame
mother Vit D concentration will assessed before starting the intervention (one month postpartum) and at the end of it (fourth month postpartum)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.